Skip to main content
. 2021 Mar 31;11:613198. doi: 10.3389/fonc.2021.613198

Table 3.

GO enrichment analysis.

GO:Term Description Count in gene set p-value1
GO:0022402 cell cycle process 8 of 890 0.0000
GO:1903047 mitotic cell cycle process 6 of 564 0.0000
GO:0000280 nuclear division 5 of 268 0.0000
GO:0051726 regulation of cell cycle 7 of 1129 0.0000
GO:0051302 regulation of cell division 4 of 179 0.0001
GO:0051301 cell division 5 of 483 0.0001
GO:1901992 positive regulation of mitotic cell cycle phase transition 3 of 65 0.0003
GO:0007059 chromosome segregation 4 of 253 0.0003
GO:0007017 microtubule-based process 5 of 605 0.0003
GO:0000910 cytokinesis 3 of 71 0.0003
GO:0071897 DNA biosynthetic process 3 of 95 0.0005
GO:0006259 DNA metabolic process 5 of 773 0.0007
GO:0051782 negative regulation of cell division 2 of 16 0.0010
GO:0007051 spindle organization 3 of 123 0.0010
GO:0000819 sister chromatid segregation 3 of 123 0.0010
GO:0000226 microtubule cytoskeleton organization 4 of 393 0.0010
GO:0140014 mitotic nuclear division 3 of 136 0.0011
GO:0000075 cell cycle checkpoint 3 of 193 0.0027
GO:0006260 DNA replication 3 of 203 0.0028
GO:0007346 regulation of mitotic cell cycle 4 of 608 0.0036
GO:0019985 translesion synthesis 2 of 41 0.0042
GO:0010564 regulation of cell cycle process 4 of 684 0.0052
GO:0045840 positive regulation of mitotic nuclear division 2 of 54 0.0056
GO:0030071 regulation of mitotic metaphase/anaphase transition 2 of 49 0.0056
GO:0000281 mitotic cytokinesis 2 of 50 0.0056
GO:0033044 regulation of chromosome organization 3 of 313 0.0066
GO:0051225 spindle assembly 2 of 70 0.0076
GO:0007052 mitotic spindle organization 2 of 70 0.0076
GO:0051303 establishment of chromosome localization 2 of 72 0.0077

GO analyses were performed using STRING (https://string-db.org/). 1Benjamini-Hochberg-corrected p-value. Only the 30 most significant GO terms were reported.

Summary of the biological processes of GO terms of the 10 target genes that showed differential relative mRNA expression in lung CSCs comparing early stages (I-II) with advanced stages (IIIA) NSCLC.